.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD23_MetforminAndErtugliflozi.MetforminAndErtugliflozi .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD23_MetforminAndErtugliflozi.MetforminAndErtugliflozi| name: | MetforminAndErtugliflozin | |
| ATC code: | A10BD23 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 60 | L |
| clearance: | 500 | mL/min |
| other parameters in model implementation | ||
Metformin and ertugliflozin is a fixed-dose combination oral antidiabetic medication. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity, widely used as first-line therapy for type 2 diabetes mellitus. Ertugliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidney, leading to increased urinary glucose excretion. The combination is approved for the treatment of type 2 diabetes to improve glycemic control in adults.
Pharmacokinetic estimates for healthy adult subjects based on publicly available data for the combination product.